2025 · 2nd Quarter (Apr 1 - June 30)

ALLIANCE FOR BIOPHARMACEUTICAL COMPETITIVENESS AND INNOVATION

Filed by THE WASHINGTON TAX & PUBLIC POLICY GROUP.

Open official filing

Source-reported fields

Filing overview

Type: 2nd Quarter - Report
Posted: Jul 8, 2025
Income: $70,000.00
Expenses: Not reported
Registrant: THE WASHINGTON TAX & PUBLIC POLICY GROUP
Client: ALLIANCE FOR BIOPHARMACEUTICAL COMPETITIVENESS AND INNOVATION
Filing UUID: ed6ca898-dd71-45a0-969a-81a0567d0ac9
Termination date: Not reported

Literal source text

Lobbying issues and bill citations

TAX · Taxation/Internal Revenue Code

Issues related to corporate and international taxation. Issues related to OECD Pillar 1 and Pillar 2 negotiations and agreements on the taxation of global income and the potential impacts on the tax base of the U.S. and its Territories. Issues related to IRC sections 11, 164(a), 951A, 250, 59A, 163(j), 168(k), 174, and 41. (H.R.1990, H.R. 574, H.R. 1062, S. 187, S. 1605, S. 2021, H.R. 1 - Sections 70301, 70302, 70321, 70322, 70323, 70331, 70361). Issues related to interest deductibility. (H.R. 1347, S. 559, S. 1688, H.R. 1 - Section 70303)

Literal federal measure citations: H.R.1990, H.R. 574, H.R. 1062, S. 187, S. 1605, S. 2021, H.R. 1, H.R. 1347, S. 559, S. 1688, H.R. 1

Relationship and amount limits

Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.